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Abstract 
Low concentrations of GDP and its stable analog uanosine 5'-O-(2-thio)diphosphate (GDPfl S) have been shown to stimulate adenylyl 
cyclase activity in canine cardiac sarcolemmal membranes independent from a phosphate transfer eaction. The mechanism of this 
stimulation was further examined. The stable GTP analog guanosine 5'-(/37-imino)triphosphate (Gpp(NH)p) increased basal adenylyl 
cyclase activity and inhibited forskolin-stimulated activity with ECho (half-maximal effective concentration) values of 0.7 p.mol/l and 10 
nmol/1, respectively. In the presence of GDPflS (5 /zmol/l), which increased basal activity by about 150%, addition of Gpp(NH)p 
inhibited adenylyl cyclase activity by up to 50% with an ECs0 value of 40 nmol/l. Activation of cardiac muscarinic acetylcholine 
receptors by carbachoi amplified this Gpp(NH)p-induced inhibition of GDPflS-stimulated adenylyl cyclase activity. The stimulatory 
effect of GDPflS and the inhibitory effect of Gpp(NH)p on GDPflS-stimulated adenylyl cyclase activity were both attenuated by 
increasing the Mg 2+ concentration r substituting Mn 2+ for Mg 2+ in the assay. Furthermore, both effects were strongly reduced or 
abolished upon pretreatment of the sarcolemmal membranes with a low concentration f the SH reagent N-ethylmaleimide (10/xmol/l). 
These results uggest that the stimulatory effect of GDPfl S on basal adenylyl cyclase activity in canine cardiac sarcolemmal membranes 
is caused by inactivation of G i proteins, which are then rendered susceptible toactivation by Gpp(NH)p and inhibitory receptors. 
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1. Introduction 
Adenylyl cyclase of cardiac sarcolemmal membranes i  
dually regulated by stimulatory and inhibitory receptors 
[ 1-3]. Both receptor effects are mediated by the activation 
of distinct guanine nucleotide-binding regulatory proteins 
(G proteins), termed G~ and G i for stimulation and inhibi- 
tion of adenylyl cyclase, respectively. Activation of a G 
protein-coupled receptor by an agonist catalyzes the re- 
lease of GDP from and binding of GTP to the a subunit of 
the interacting G protein. Binding of GTP is followed by a 
further conformational change of the G protein, leading to 
the dissociation of the G protein /37 dimer from the 
GTP-liganded a subunit. At this step, the G protein is in 
its active confirmation and either the GTP-bound a sub- 
unit and/or the free /37 dimer then regulate activities of 
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responsive ffectors uch as adenylyl cyclase. The a sub- 
unit carries an intrinsic GTPase activity which hydrolyzes 
the bound GTP to GDP. The GDP-bound a subunit is 
inactive in terms of effector regulation and has an in- 
creased affinity for/37 dimers. Hence, the subunits reasso- 
ciate and may be reactivated by a receptor. These reaction 
steps are thought o be common to all members of the G 
protein family, including G i and G~ [4-6]. 
We have recently reported that basal adenylyl cyclase 
activity of canine cardiac sarcolemmal membranes i not 
only increased by GTP and its stable analog, guanosine 
5'-( flT-imino)triphosphate (Gpp(NH)p), but that the gua- 
nine nucleoside diphosphate GDP can also stimulate basal 
enzyme activity [7]. This GDP-dependent s imulation of 
cardiac adenylyl cyclase, which occurs at submicromolar 
concentrations (ECs0 value of about 0.1 /zmol/l GDP), 
was not affected by inhibiting phosphotransfer r actions. 
Furthermore, the GDP analog, guanosine 5'-O-(2-thio)di- 
phosphate (GDP/3 S), mimicked the effect of GDP to stim- 
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ulate cardiac adenylyl cyclase activity at low concentra- 
tions, with an ECs0 value of about 0.4 /zmol/l [7]. Thus, 
the guanine nucleoside diphosphates GDP and GDP/3S, 
generally considered to keep G proteins in their inactive 
state and/or to competitively inhibit G protein activation 
by GTP and its analogs, increased instead of inhibiting 
cardiac adenylyl cyclase activity. Since cardiac adenylyl 
cyclase is dually regulated by G~ and G i proteins, as is the 
enzyme activity in most other cell types, the observed 
adenylyl cyclase stimulatory actions of the guanine nucleo- 
side diphosphates are most likely due to an 'inhibitory' 
action on G i proteins, eventually resulting in adenylyl 
cyclase stimulation. The present study was performed to 
characterize this effect and thus to understand the unex- 
pected finding of GDP stimulation of adenylyl cyclase. It 
is shown here that stimulation of canine cardiac sarcolem- 
mal adenylyl cyclase by GDP/3S is potently inhibited by 
the stable GTP analog Gpp(NH)p, that this inhibition is 
amplified by the muscarinic acetylcholine r ceptor agonist 
carbachol, and that both stimulation of adenylyl cyclase by 
GDPfl S and inhibition of this activity by Gpp(NH)p are 
strongly reduced by agents interfering with Gi protein 
function. 
(w/w) to unmask latent adenylyl cyclase activity. This 
peptide ionophore increases the accessibility of substrates 
to the adenylyl cyclase in sealed sarcolemmal vesicles 
without affecting the functional coupling to receptors [8]. 
Omission of alamethicin revealed lower overall adenylyl 
cyclase activity, however, the effects of guanine nu- 
cleotides were not altered. The adenylyl cyclase reaction 
was started by the addition of membrane protein and 
continued for 10-15 min at 37°C. Under these conditions, 
adenylyl cyclase activity was linear with time (1-20 min) 
and protein (0.1-3 /zg). Protein was determined, using the 
Bradford-Bio-Rad dye-binding assay. 
2.4. NEM pretreatment ofsarcolemmal membranes 
When appropriate, and concurrent with alamethicin 
treatment, membranes were pretreated with NEM (10 
/zmol/1 final concentration) for 15 min on ice. The alkyla- 
tion reaction was stopped by the addition of 4 mmol/l 
dithiothreitol. Control membranes for these experiments 
received ithiothreitol nly. 
2.5. Statistical analysis 
2. Materials and methods 
2.1. Materials 
Alamethicin, N-ethylmaleimide (NEM) and carbachol 
were purchased from Sigma (Deisenhofen, Germany). ATP, 
Gpp(NH)p and GDP/3 S were from Boehringer Mannheim 
(Mannheim, Germany). [a-32p]ATP was from DuPont- 
New England Nuclear (Bad Homburg, Germany). 
2.2. Purification of sarcolemmal membranes 
Purified sarcolemmal membranes were prepared from 
beagle hearts according to Jones et al. [8]. Membranes 
were frozen in liquid nitrogen and stored at -80°C. 
Adenylyl cyclase activity was stable over a period of six 
months when stored under these conditions. 
2.3. Measurement ofadenylyl cyclase activity 
Adenylyl cyclase activity of canine cardiac sarcolemmal 
membranes was determined in the absence of a nucleoside 
triphosphate-regenerating system by measuring the conver- 
sion of [ a -32 P]ATP to [32p]cAMP, according to Jakobs et 
al. [9]. The assay volume was 100 /zl containing 0.1 
mmol/l ATP with (2-5)X 105 cpm of [a-32p]ATP, 3 
mmol/l MgC12 (unless otherwise indicated), 0.1 mmol/1 
cAMP, 1 mmol/1 EDTA, 0.5 mmol/1 dithiothreitol, 0.05 
mg bovine serum albumin, and 75 mmol/l  Tris-HCl (pH 
7.6). The membranes (2.5-3 /zg protein) were preincu- 
bated with alamethicin for 20 min at 4°C at a 1 : 1 ratio 
All results are expressed as means _ standard eviation 
of at least three separate xperiments with triplicate deter- 
minations. To compare the mean values of multiple groups, 
repeated measure one-way ANOVA was carried out fol- 
lowed by post-tests if significant. Comparisons between 
two groups were carried out using paired t tests. 
3. Results 
Basal adenylyl cyclase activity in canine cardiac sar- 
colemmal membranes was increased by the stable GTP 
analog Gpp(NH)p by maximally 160% (P < 0.01). Half- 
maximal and maximal activation was observed at 0.7 
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Fig. 1. Stimulation of basal cardiac adenylyl cyclase activity by 
Gpp(NH)p. Basal adenylyl cyclase activity of canine cardiac sarcolemmal 
membranes was determined atthe indicated concentrations of Gpp(NH)p. 
Values are the means + standard eviation (SD) of four separate xperi- 
ments. 
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/xmol/1 and 5 /zmol/1 Gpp(NH)p, respectively (Fig. 1). 
The diterpene forskolin (5 /zmol/ l)  stimulated cardiac 
adenylyl cyclase 13-fold (from 1.26 _+ 0.2 to 18.31 _+ 1.4 
nmol/min per mg protein). Gpp(NH)p-mediated inhibition 
of forskolin-stimulated nzyme activity was evident at 
much lower concentrations of Gpp(NH)p than those re- 
quired for stimulation of basal activity. Half-maximal and 
maximal inhibition (40%, P < 0.01) of forskolin-stimu- 
lated activity was observed at about 10 nmol/1 and 100 
nmol/ l  Gpp(NH)p, respectively. The stable GDP analog, 
GDP/3S, increased basal adenylyl cyclase activity in ca- 
nine cardiac sarcolemmal membranes by 150% (Fig. 2, 
P < 0.01), with half-maximal and maximal effects occur- 
ring at about 0.4/zmol/1 and 5/zmol/1, respectively (data 
shown in reference 7). Co-addition of Gpp(NH)p did not 
result in further stimulation, instead Gpp(NH)p potently 
reduced GDP/3S (5 /xmol/1)-stimulated a enylyl cyclase 
activity (Fig. 2). At concentrations up to 1 /zmol/1, 
Gpp(NH)p now reduced enzyme activity by 50% (P  < 
0.01), with half-maximal inhibition occurring at about 40 
nmol/ l  Gpp(NH)p. At higher concentrations, the in- 
hibitory effect of Gpp(NH)p decreased and eventually, at a 
concentration of 100 /zmol/1, was no longer observed. 
Increasing the free magnesium concentration in the 
assay from 2 mmol/ l  to 5 or 10 mmol/1 enhanced basal 
adenylyl cyclase activity by 190% and 360%, respectively 
(Fig. 3A). The absolute increase in basal enzyme activity 
caused by the two guanine nucleotides, GDP/3 S (5/zmol/1) 
and Gpp(NH)p (1 /zmol/l), also increased. When ex- 
pressed relative to basal activity, Gpp(NH)p-stimulated 
activity was not altered by increasing the concentration of 
free Mg 2+ from 2 mmol/ l  to 5 mmol/1, and was reduced 
from 170 to 125% stimulation at 10 mmol/ l  free Mg 2+ 
(Fig. 3B). On the other hand, GDP/3S stimulation of 
adenylyl cyclase activity was much more sensitive to 
increases in Mg 2+ concentration. Relative to basal activ- 
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Fig. 3. Influence of Mg 2+ on cardiac adenylyl cyclase stimulation a d 
inhibition by GDP/3S and Gpp(NH)p. Adenylyl cyclase activity of canine 
cardiac sarcolemmal membranes was determined in the absence and 
presence ofGDPflS (5/zmol/l), Gpp(NH)p (1 /xmol/l) or the combina- 
tion of these two nucleotides with either 2 mmol/l, 5 mmol/1 or 10 
mmol/1 free Mg -~+, as indicated. Absolute nzyme activities are given in 
A, while in B activities inthe presence ofGDP/3 S- ,  Gpp(NH)p- and 
GDPfl S + Gpp(NH)p are shown relative to the respective basal activities 
measured atthe different Mg 2+ concentrations. Values are the means 5:
SD of three separate experiments where * * and * indicate P < 0.01 and 
0.05, respectively. 
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Fig. 2. Influence of Gpp(NH)p on cardiac adenylyl cyclase activity in the 
presence of GDPflS. Adenylyl cyclase activity of canine cardiac sar- 
colemmal membranes was determined in the presence of 5 /~mol/l 
GDP/3 S and the indicated concentrations of Gpp(NH)p. Values are the 
means -4- SD of three separate xperiments. 
170% stimulation at 2 mmol/1 Mg 2+ to only 120% at 5 
mmol/ l  free Mg 2+ (P  < 0.01), and at 10 mmol/ I  free 
Mg 2+ GDP/3 S increased adenylyl cyclase activity by only 
85% (P  < 0.01 compared to relative increase at 2 mmol/ l  
Mg 2+ ). Inhibition of adenylyl cyclase activity in the pres- 
ence of GDP/3 S by Gpp(NH)p decreased from 40% at 2 
mmol/ l  Mg 2+ to 13% at 10 mmol/1 Mg 2+ (P  < 0.01). 
Adenylyl cyclase activity measured in the presence of both 
GDPfl S and Gpp(NH)p remained at the same level com- 
pared to basal activity, i.e. 55-60% higher, at all concen- 
trations of free Mg 2+ studied. Thus, the relative stimula- 
tory effects of GDP/3S and inhibition of GDP/3S-stimu- 
lated adenylyl cyclase activity by Gpp(NH)p were reduced 
to the same extent by increasing the free Mg 2+ concentra- 
tion. 
When the MgC12 in the assay was replaced with MnCI 2 
(total concentration 1.5 mM), basal activity increased by 
240% (Fig. 4). Under these conditions, GDP/3 S-mediated 
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Fig. 4. Effects of Mn 2+ on cardiac adenylyl cyclase stimulation and 
inhibition by GDP/3S and Gpp(NH)p, respectively. Adenylyl cyclase 
activity was determined in the absence and presence of GDP/3S (5 
/zmol/1) or GDP/3S (5/zmol/1) plus Gpp(NH)p (1 p.mol/1) as indicated 
with either 2 mmol/1 free Mg 2+ or 0.5 mmol/ l  free Mn 2÷. Values are 
the means + SD of five separate xperiments where * * indicates P < 
0.01. 
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Fig. 6. Inhibition of cardiac adenylyl cyclase activity by Gpp(NH)p and 
carbachol in the presence of GDPflS. Adenylyl cyclase activity of canine 
cardiac sarcolemmal membranes was determined in the absence and 
presence of carbachol (10 /zmol/1) and either GDP/3S (5 /zmol/1), 
Gpp(NH)p (1 /zmol/l) or the combination of GDPflS (5 /zmol/1) and 
Gpp(NH)p (1 /zmol/1) as indicated. Values are the means + SD of three 
separate xperiments where * indicates P < 0.05. 
stimulation of adenylyl cyclase activity was reduced by 
85%. Inhibition of GDP/3S-stimulated adenylyl cyclase 
activity by Gpp(NH)p was also reduced and no more 
significant. 
Pretreatment of canine cardiac sarcolemmal membranes 
for 15 min with the SH reagent, NEM (10 /zmol/l), 
caused an increase of 30% in basal adenylyl cyclase 
activity, measured in the absence of guanine nucleotides 
(Fig. 5, P < 0.01). The relative increase in adenylyl cy- 
clase activity caused by GDP/3 S (5 /zmol/l) was reduced 
in membranes pretreated with NEM (160 and 70% stimula- 
tion for control and NEM-treated membranes, respectively, 
P<0.01). However, absolute values of GDPflS-stimu- 
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Fig. 5. Influence of NEM pretreatment on regulation of cardiac adenylyl 
cyclase activity by GDP/3S and Gpp(NH)p. Canine cardiac sarcolemmal 
membranes were pretreated for 15 min on ice with or without (control) 10 
/zmol/l NEM, followed by addition of 4 mmol/ l  dithiothreitol to stop 
the alkylation reaction. In these pretreated membranes, adenylyl cyclase 
activity was determined in the absence and presence of GDP/3S (5 
/zmol/l) or GDPflS (5 /xmol/1) plus Gpp(NH)p (1 /zmol/1) as indi- 
cated. Values are the means + SD of five separate xperiments where * * 
indicates P < 0.01. 
lated activity did not differ significantly. Most obviously, 
whereas Gpp(NH)p (1 /zmol/l) reduced adenylyl cyclase 
activity in the presence of GDP/3S (5 /zmol/l) by 35% in 
control sarcolemmal membranes, this inhibition was virtu- 
ally abolished in membranes pretreated with the alkylating 
SH reagent (Fig. 5). 
Addition of the muscarinic acetylcholine r ceptor ago- 
nist carbachol (10 /zmol/1) to purified canine cardiac 
sarcolemmal membranes had no effect on adenylyl cyclase 
activity in the absence of added guanine nucleotides (Fig. 
6). Furthermore, carbachol did not inhibit adenylyl cyclase 
activity stimulated by Gpp(NH)p (1 /zmol/1) alone, and 
only marginally inhibited adenylyl cyclase stimulated by 
GDP/3 S (5/zmol/1). In contrast, in the presence of GDP/3 S 
(5 /zmol/l), inhibition of adenylyl cyclase induced by 
Gpp(NH)p (1 /zmol/1) was increased from 30% to 60% 
when carbachol (10 izmol/1) was added (P < 0.05). The 
effect of carbachol on adenylyl cyclase activity in the 
presence of guanine nucleotides was blocked by the mus- 
carinic receptor antagonist atropine (100 /xM) and by 
pretreatment of the sarcolemmal membranes with pertussis 
toxin and NAD (data not shown). 
4. Discussion 
Studies on different membrane systems, including car- 
diac membranes, have shown an activation of adenylyl 
cyclase by GDP and its analog GDPflS, which is appar- 
ently independent of transphosphorylation reactions cat- 
alyzed by nucleoside diphosphate kinase [7,10-12]. The 
mechanism of this unexpected stimulation, however, is as 
yet unclear. G proteins are the only known targets for 
regulatory effects of guanine nucleotides on adenylyl cy- 
clase activity. Thus, excluding the presence of a novel, but 
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as yet unidentified GDP-binding protein, the observed 
stimulatory effects of GDP and GDP/3 S on cardiac adeny- 
lyl cyclase activity are most likely due to an action at G~ 
or Gi proteins, the G proteins primarily regulating adenylyl 
cyclase activity [13]. 
That the observed stimulation of adenylyl cyclase activ- 
ity by GDP and GDP/3 S is due to activation of G~ proteins 
is unlikely for the following reasons. First, it has been 
shown in many different membrane systems and in recon- 
stitution studies with purified components that only the 
GTP- or stable GTP analog-liganded G~ protein is capable 
of stimulating adenylyl cyclase activity, whereas GDP/3S 
is either inactive or inhibitory (or reviews ee [4], [5], [13]). 
Second, phosphorylation f GDP to GTP and subsequent 
activation of G~ can also be ruled out as the mechanism of 
adenylyl cyclase activation, since activation by GDP oc- 
curred even when transphosphorylation t  form GTP was 
completely prevented [7]. Moreover, GDP/3S was equally 
effective in stimulating cardiac adenylyl cyclase activity, 
mimicking GDP's stimulatory action at low concentrations 
[7], despite being known as a poor substrate for phosphate 
transfer eactions [14,15]. Thus, it seems feasible to as- 
sume that stimulation of cardiac adenylyl cyclase activity 
by GDP and GDP/3S is due to an action on the adenylyl 
cyclase inhibitory Gi proteins rather than to activation of 
stimulatory G~ proteins. This hypothesis implies that 
'basal' adenylyl cyclase activity (i.e. without he addition 
of any stimulatory or inhibitory agent including guanine 
nucleotides) in cardiac sarcolemmal membranes i under 
inhibitory control by G~ proteins, and that GDP/3S, by 
binding to G~ c~ subunits, relieves this inhibition. Such a 
hypothesis, furthermore, implies that G~ proteins in cardiac 
membrane preparations are active, at least in terms of 
adenylyl cyclase inhibition, in the absence of bound gua- 
nine nucleotides. 
Several findings presented in this study support the 
hypothesis that GDP/3S stimulation of cardiac adenylyl 
cyclase is caused by an inhibitory action at G, proteins. 
First, the stable GTP analog Gpp(NH)p, which increased 
basal activity, potently inhibited GDP/3 S-stimulated adeny- 
lyl cyclase activity by up to 50%. The concentrations of 
Gpp(NH)p necessary for this inhibitory effect were much 
lower than those required for stimulation of basal adenylyl 
cyclase activity. Half-maximal inhibition of GDP/3S- 
stimulated enzyme activity was observed at about 40 
nmol/l Gpp(NH)p, while a 25-fold higher concentration (1 
/zmol/l) of Gpp(NH)p was required for half-maximal 
stimulation of basal activity. The former value (40 nmol/1) 
is in close agreement with the potency of Gpp(NH)p (10 
nmol/1) to inhibit forskolin-stimulated a enylyl cyclase 
activity. The small, factor 4 difference between these two 
values is most likely due to the fact that inhibition of 
forskolin-stimulated activity by Gpp(NH)p was studied in 
the presence of Gpp(NH)p alone, while in the study on 
inhibition of GDP/3S-stimulated a enylyl cyclase activity 
by Gpp(NH)p, GDP/3 S was additionally present at a con- 
centration of 5 /~mol/l and would have competed with 
Gpp(NH)p for binding to G proteins. Thus, in the presence 
of GDP/3S, an adenylyl cyclase inhibitory action of 
Gpp(NH)p by activation of G i proteins becomes apparent. 
The reversal of GDP/3 S-stimulated adenylyl cyclase inhibi- 
tion at Gpp(NH)p concentrations greater than 1 /zmol/l 
was likely to be a consequence of Gpp(NH)p binding to, 
and subsequently activating, GS proteins. 
It has been reported in various membrane systems that 
inhibitory receptor- and G i protein-mediated inhibition of 
adenylyl cyclase is decreased by increasing the free Mg 2+ 
concentration [ 16-18]. Therefore, the influence of various 
Mg 2+ concentrations was studied on the adenylyl cyclase 
stimulatory effect of GDP/3S and its inhibition by 
Gpp(NH)p. The relative stimulatory effect of GDP/3 S on 
basal adenylyl cyclase activity and the inhibition of 
GDP/3S-stimulated a enylyl cyclase by Gpp(NH)p were 
reduced with similar sensitivities by increasing Mg 2+ 
concentrations. On the other hand, stimulation of basal 
enzyme activity by Gpp(NH)p, due to activation of Gs 
proteins, was clearly less sensitive to increases in Mg 2+ 
concentration. This finding suggests that stimulation of 
basal adenylyl cyclase activity in canine cardiac sarcolem- 
real membranes by GDP/3S and inhibition of this stimula- 
tion by Gpp(NH)p are due to an action at a common 
regulatory site, i.e. G~ proteins. 
The effect of substitution of Mg 2+ with Mn 2+ in the 
assay further suggested an action of GDP/3 S at G i pro- 
teins. When employed at low concentration, Mn 2 + prefer- 
entially perturbs the G i protein interaction with adenylyl 
cyclase [19-21]. Although Mn 2+ increased the activity of 
adenylyl cyclase in the absence of added guanine nu- 
cleotides, most likely by directly activating the enzyme 
catalytic subunit, both stimulation of adenylyl cyclase by 
GDP/3S and inhibition of this stimulation by Gpp(NH)p 
were attenuated. 
The SH reagent NEM has a selective effect on G~ 
proteins when employed at low concentrations and under 
mild pretreatment conditions, e.g. at 4°C. NEM pretreat- 
ment has been shown to cause alkylation of Gi/G o pro- 
teins at two [22] or three [23] distinct sites, one of which is 
the cysteine residue target for pertussis toxin-catalysed 
ADP-ribosylation. Since NEM increased basal adenylyi 
cyclase activity (even in the absence of GTP) it may, in 
contrast o pertussis toxin, inhibit G i function at a site 
distinct from the receptor interaction domain. Despite in- 
creased basal activity, the absolute value of adenylyl cy- 
clase activity in the presence of a maximally stimulatory 
concentration of GDP/3S remained constant after NEM 
pretreatment. Thus, the relative stimulatory effect of 
GDP/3 S was strongly reduced from 160% stimulation in 
membranes pretreated without NEM to only 70% stimula- 
tion in NEM-pretreated membranes. Most obviously, the 
inhibition of GDP/3 S-stimulated adenylyl cyclase activity 
by Gpp(NH)p was inhibited after pretreatment of cardiac 
membranes with the SH reagent. Thus, both GDP/3S-in- 
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duced stimulation of basal adenylyl cyclase activity and 
Gpp(NH)p-induced inhibition of this stimulated activity 
were strongly reduced or abolished by NEM treatment, 
suggesting that a similar target, most likely G i proteins, 
are mediating these two effects on cardiac adenylyl cy- 
clase. 
Finally, we studied whether GDP/3 S-stimulated cardiac 
adenylyl cyclase activity is subject to regulation by the 
inhibitory muscarinic acetylcholine receptor [1-3]. The 
receptor agonist carbachol had no effects on adenylyl 
cyclase activity in the absence of guanine nucleotides, or 
in the presence of GDP]3 S or Gpp(NH)p alone. The inef- 
fectiveness of stable GTP analogs to support receptor- 
mediated inhibition of adenylyl cyclase has been noted 
previously [24-29] and has led to misleading conclusions 
[29,30]. In the present study, however, addition of GDP/3 S 
discloses an inhibition of adenylyl cyclase by Gpp(NH)p 
and the muscarinic receptor agonist carbachol. The effec- 
tiveness of carbachol plus Gpp(NH)p to inhibit adenylyl 
cyclase activity only in the presence of GDP/3 S is inter- 
preted to be due to the receptor-mediated r lease of GDP/3 S 
[31] and subsequent binding of Gpp(NH)p to G i proteins. 
This finding indicates that activation of G i proteins by 
stable GTP analogs follows commonly described mecha- 
nisms. It should be noted that complete reversal of 
GDPflS-stimulated adenylyl cyclase by Gpp(NH)p alone 
was not observed, most likely due to its action at both G i 
and G~ proteins. However, further addition of carbachol 
resulted in a full reversal of GDP/3S-stimulated a enylyl 
cyclase activity (Fig. 6). Hence the magnitude of the 
combined effect of Gpp(NH)p and carbachol exactly corre- 
spond to the effects of GDP/3 S, indicating that the mecha- 
nism of GDP/3 S stimulation of adenylyl cyclase activity is 
entirely due to the relief of inhibition by G i proteins. 
In conclusion, the data of the present study suggest that 
the stimulatory effect of GDPfl S, and most likely also of 
GDP, on adenylyl cyclase activity in canine cardiac sar- 
colemmal membranes i  due to an inhibitory interaction at 
Gi proteins, resulting in a relief of the inhibitory effect of 
these G proteins on adenylyl cyclase activity. This inhibi- 
tion seems to be caused by guanine nucleotide-free Gi
proteins. Following 'inactivation' by GDPfl S, G~ proteins 
can apparently be reactivated by a GTP analog and by 
agonist-activated muscarinic acetylcholine r ceptors. 
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